

## 10      **acalabrutinib**

ment at baseline, discontinue and do NOT restart; measure serum total bilirubin, AST/ALT if hepatotoxicity is suspected; elevations of AST, ALT, bilirubin from baseline should prompt more frequent monitoring

- Monitor B/P, pulse, edema, if hypertensive, control symptoms

- **Musculoskeletal pain, joint swelling, discomfort:** arthritis, arthralgia, joint swelling, and joint stiffness, some severe; muscle discomfort that includes muscle spasms, musculoskeletal pain, myalgia, musculoskeletal discomfort, and musculoskeletal stiffness may be relieved with analgesics

- Signs, symptoms of adrenocorticoid insufficiency (anorexia, nausea, vomiting, fatigue, weight loss); corticosteroids may need to be prescribed during stress, trauma, surgery; assess monthly for hypertension, hypokalemia, fluid retention

- **QT prolongation:** monitor ECG for QT prolongation, ejection fraction in patients with cardiac disease; small increases in the QTc interval such as <10 ms have occurred; monitor for arrhythmia exacerbation such as sinus tachycardia, atrial fibrillation, supraventricular tachycardia (SVT), atrial tachycardia, ventricular tachycardia, atrial flutter, bradycardia, AV block complete, conduction disorder, bradyarrhythmia

### **Evaluate:**

- Therapeutic response: Decreasing spread, progression of prostate cancer

### **Teach patient/family:**

- **Pregnancy:** that women must not come into contact with tabs; to wear gloves if product needs to be handled; that males should wear condoms and use another form of contraception if partner is pregnant during use of product and for 1 wk after discontinuing treatment

- To report chest pain, swelling of joints, burning/pain when urinating

- Not to use with other medications, herbs without prescriber approval

- To take 2 hr before or 1 hr after meals; to swallow tab whole, take with water

- That this product, predniSONE, and a GnRH need to be used together

- Not to stop abruptly without prescriber consent

**⚠ HIGH ALERT**

**RARELY USED**

### **acalabrutinib**

Calquence

*Func. class.:* Antineoplastic

**USES:** For the treatment of mantle cell lymphoma (MCL) in patients who have received at least 1 prior therapy

### **DOSAGE AND ROUTES**

For the treatment of mantle cell lymphoma (MCL) in patients who have received at least 1 prior therapy

- **Adult: PO** 100 mg bid (approximately 12 hr apart) until disease progression

### **acamprosate (Rx)**

(a-kam-pro'sate)

Campral 

*Func. class.:* Alcohol deterrent

*Chem. class.:* Synthetic amino acid neurotransmitter analog

**ACTION:** Not completely understood; in vitro data suggest it has affinity for type A and type B GABA receptors, lowers neuronal excitability, centrally mediated

**USES:** Alcohol abstinence management

### **CONTRAINDICATIONS**

Hypersensitivity to this product or sulfites, creatinine clearance  $\leq 30$  mL/min

**Precautions:** Pregnancy, breastfeeding, infants, children, ethanol intoxication, renal impairment, depression, suicidal ideation, driving or operating machinery, geriatric patients

### **DOSAGE AND ROUTES**

- **Adult: PO** 666 mg tid

#### **Renal dosage**

- **Adult: PO** CCr 30-50 mL/min 333 mg tid; CCr <30 mL/min do not use

**Available forms:** Del-rel tabs 333 mg